Compare Bristol-Myers Squibb Co (BMY) vs Coursera Inc (COUR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Coursera Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.98 (market cap $129.94B), while Coursera Inc trades at $5.55 (market cap $1.50B). The key difference: Bristol-Myers Squibb Co is far larger — about 86.6× Coursera Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Coursera Inc pays none. Which is the better fit depends on your goals.
| BMY | COUR | |
|---|---|---|
Market Cap | $129.94B | $1.50B |
Sector | Health | Consumer Staples |
52-Week High | $65.89 | $12.20 |
52-Week Low | $42.60 | $5.09 |
Enterprise Value | $163.92B | $759.54M |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
COUR trades at $5.76, down 0.86% today, with a neutral technical signal. Revenue grew to $757.5M in 2025, but net income remains negative at -$51M. The company recently beat Q2 2026 EPS estimates at $0.17 versus $0.10 expected. Positive cash flow from operations of $108.7M in 2025 supports liquidity, while a $100M investment in LearnVector highlights strategic AI focus.
Outlook is mixed: analyst consensus is bullish with a $7.70 price target (34% upside), but persistent losses and competitive pressures pose risks. The stock offers growth potential if profitability improves, yet high SG&A costs and integration challenges from the Udemy acquisition require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →
